Results 1 to 10 of about 87 (78)

The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application

open access: yesMediators of Inflammation, Volume 2022, Issue 1, 2022., 2022
Hyperlipidemia is a common metabolic disorder with high morbidity and mortality, which brings heavy burden on social. Understanding its pathogenesis and finding its potential therapeutic targets are the focus of current research in this field. In recent years, an increasing number of studies have proved that miRNAs play vital roles in regulating lipid ...
Yu Xiang   +6 more
wiley   +1 more source

NGLY1 deficiency: Novel patient, review of the literature and diagnostic algorithm

open access: yesJIMD Reports, Volume 51, Issue 1, Page 82-88, January 2020., 2020
Abstract Objectives Together with the lysosomal storage diseases, NGLY1 deficiency is a congenital disorder of deglycosylation (NGLY1‐CDDG). Since the first report in 2012, 26 patients have been described. All but one were diagnosed by exome or genome sequencing; the remaining one was identified by finding an increased concentration of an urinary ...
Patryk Lipiński   +4 more
wiley   +1 more source

Acquired Hypolipoproteinemia

open access: yesClinical Chemistry, 1992
Abstract We present a six-year follow-up of a boy with a novel type of hypolipoproteinemia, with clinical and biochemical features distinct from classical hypoalphalipoproteinemias. There were abnormally low concentrations of total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) B, apo A-I, and apo A-II, and the ...
M, De Buyzere   +6 more
openaire   +2 more sources

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy

open access: yesCanadian Journal of Gastroenterology and Hepatology, Volume 2018, Issue 1, 2018., 2018
Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people. Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatment. Currently, direct‐acting antiviral drugs (DAA) are
Sylvia Drazilova   +4 more
wiley   +1 more source

Autoimmune Lymphoproliferative Syndrome: A Rare Cause of Disappearing HDL Syndrome

open access: yesCase Reports in Immunology, Volume 2016, Issue 1, 2016., 2016
The term disappearing HDL syndrome refers to development of severe high density lipoprotein cholesterol (HDL‐C) deficiency in noncritically ill patients with previously normal HDL‐C and triglyceride levels. Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of the immune system due to an inability to regulate lymphocyte homeostasis resulting ...
Swetha Sriram   +4 more
wiley   +1 more source

The monocyte/high-density lipoprotein cholesterol ratio in patients with primary hypolipoproteinemia

open access: yesJournal of Medicine and Palliative Care, 2022
Aim: Hypolipoproteinemia is low blood lipid levels in adults. Primary hypolipoproteinemia due to genetic mutations is a rare condition. Studies to demonstrate the clinical significance of hypolipoproteinemia are limited. It was aimed to evaluate the clinical and laboratory characteristics of patients with primary hypolipoproteinemia and the monocyte ...
openaire   +2 more sources

Acquired Hypolipoproteinemia and Hemophagocytic Lymphohistiocytosis: A Case Series and Review

open access: yesHematology Reports
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by uncontrolled macrophage activation. Secondary HLH is more common in adults and may be triggered by infection, malignancy, or autoimmune disease.
Leo Reap   +3 more
openaire   +1 more source

Hypolipoproteinemia and hyperinflammatory cytokines in serum of severe and moderate traumatic brain injury (TBI) patients.

open access: yesEuropean cytokine network, 2007
Traumatic brain injury (TBI) acts as an inducer of the inflammatory reaction expressed by the release of pro-inflammatory cytokines (interleukin-1beta [IL-1beta], interleukin-6 [IL-6] and interleukin-8 [IL-8]), and causes metabolic alterations in the early, post-traumatic state, either in the brain or/and the systemic circulation. The metabolic changes
Venetsanou, K.   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy